Search results
Your search for follwing guidelines returned no results
Showing 601 to 650 of 1121 results for following guidelines
Showing 601 to 650 of 1121 results for following guidelines
This guide describes the process NICE uses to develop NICE quality standards
Icare rebound tonometer to measure intraocular pressure (MIB57)
NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Occipital nerve stimulation for intractable chronic migraine (HTG310)
Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.
View recommendations for HTG310Show all sections
Sections for HTG310
Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (HTG148)
Evidence-based recommendations on arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis. This involves flushing the joint with fluid, which is introduced through small incisions in the knee.
View recommendations for HTG148Show all sections
Sections for HTG148
This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.
View recommendations for PH51Show all sections
NPi-200 for pupillary light reflex in critical care patients (MIB235)
NICE has developed a medtech innovation briefing (MIB) on NPi-200 for pupillary light reflex in critical care patients .
Transcranial magnetic stimulation for treating and preventing migraine (HTG330)
Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.
Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.
View recommendations for HTG639Show all sections
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.
Transabdominal artificial bowel sphincter implantation for faecal incontinence (HTG177)
Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.
View recommendations for HTG177Show all sections
Sections for HTG177
Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.
Dexcom G6 for real-time continuous glucose monitoring (MIB233)
NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.